Trial · NCT01609062
Adverse events354
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 354
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Lymph node pain | Blood and lymphatic system disorders | BMN 110 Weekly at 2.0 mg/kg/Week | 1 | 15 | 1 |
| other | Lymph node pain | Blood and lymphatic system disorders | BMN 110 Weekly at 4.0 mg/kg/Week | 0 | 10 | 0 |
| other | Bradycardia | Cardiac disorders | BMN 110 Weekly at 2.0 mg/kg/Week | 1 | 15 | 1 |
| other | Bradycardia | Cardiac disorders | BMN 110 Weekly at 4.0 mg/kg/Week | 0 | 10 | 0 |
| other | Sinus bradycardia | Cardiac disorders | BMN 110 Weekly at 2.0 mg/kg/Week | 0 | 15 | 0 |
| other | Sinus bradycardia | Cardiac disorders | BMN 110 Weekly at 4.0 mg/kg/Week | 1 | 10 | 1 |
| other | Tachycardia | Cardiac disorders | BMN 110 Weekly at 2.0 mg/kg/Week | 0 | 15 | 0 |
| other | Tachycardia | Cardiac disorders | BMN 110 Weekly at 4.0 mg/kg/Week | 1 | 10 | 2 |
| other | Pectus carinatum | Congenital, familial and genetic disorders | BMN 110 Weekly at 2.0 mg/kg/Week | 1 | 15 | 1 |
| other | Pectus carinatum | Congenital, familial and genetic disorders | BMN 110 Weekly at 4.0 mg/kg/Week | 0 | 10 | 0 |
| other | Ear discomfort | Ear and labyrinth disorders | BMN 110 Weekly at 2.0 mg/kg/Week | 0 | 15 | 0 |
| other | Ear discomfort | Ear and labyrinth disorders | BMN 110 Weekly at 4.0 mg/kg/Week | 1 | 10 | 1 |
| other | Ear pain | Ear and labyrinth disorders | BMN 110 Weekly at 2.0 mg/kg/Week | 2 | 15 | 3 |
| other | Ear pain | Ear and labyrinth disorders | BMN 110 Weekly at 4.0 mg/kg/Week | 2 | 10 | 2 |
| other | Ear pruritus | Ear and labyrinth disorders | BMN 110 Weekly at 2.0 mg/kg/Week | 1 | 15 | 1 |
| other | Ear pruritus | Ear and labyrinth disorders | BMN 110 Weekly at 4.0 mg/kg/Week | 0 | 10 | 0 |
| other | Motion sickness | Ear and labyrinth disorders | BMN 110 Weekly at 2.0 mg/kg/Week | 2 | 15 | 3 |
| other | Motion sickness | Ear and labyrinth disorders | BMN 110 Weekly at 4.0 mg/kg/Week | 0 | 10 | 0 |
| other | Otorrhoea | Ear and labyrinth disorders | BMN 110 Weekly at 2.0 mg/kg/Week | 1 | 15 | 1 |
| other | Otorrhoea | Ear and labyrinth disorders | BMN 110 Weekly at 4.0 mg/kg/Week | 0 | 10 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01609062/events